MYCOF News and Press, New Age Brands From 12/29/21

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) , a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed ...

New research has found evidence that an extensive range of early onset psychiatric issues like ADHD, bulimia, dyslexia, anxiety and depression are primarily caused by psychological, social and biological factors. The objective of the study, which was conducted by scientists at McGill Uni...

Voters in the state of Colorado may get the chance to vote to legalize the growing and possession of psychedelic substances next year, as well as establish a system of licensed businesses to produce psychedelics such as ibogaine, DMT and psilocybin to be used at healing centers. This comes...

A recently conducted survey has found that only 50% of parents who tried acquiring mental health services for their children during the coronavirus pandemic were successful in their attempts. The survey was carried out in September 2021 by DotCom Therapy, a pediatric teletherapy provider. ...

DENVER, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, an...

A recently conducted survey has discovered that during the coronavirus pandemic, individuals who use drugs recreationally have been microdosing on psychedelic substances to improve their mental health. Researchers believe that this discovery shows that some individuals living with mental h...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with ...

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space  The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022 Mydecine has put systems a...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessa...

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers t...